Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.775    0.00 (0.00%)
Bid:
1.55
Ask:
1.99
Spread: 0.44 (28.387%)
Market Cap: £6.23m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Holding(s) in Company

21 Mar 2007 07:00

Proteome Sciences Plc ("the Company") Notifiable Interest

A form TR-1 containing the following information has been received by the Company.

TR-1 notification of major interests in shares

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Proteome Sciences Plc

2. Reason for the notification

Revised due to DTR rules - see section 13

3. Full name of person(s) subject to the notification obligation:

FMR Corp

4. Full name of shareholder(s) (if different from 3):

Fidelity Management & Research Company (FMRCO)

5. Date of the transaction (and date on which the threshold is crossed or reached if different):

Revised due to DTR rules

6. Date on which issuer notified:

20 March 2007 (by fax & post)

7. Threshold(s) that is/are crossed or reached:

N/A

8. Notified details:

A: Voting rights attached to shares

Class/type of Situation Resulting situation after the triggering shares previous to transaction Triggering if possible transaction Notification required under DTR transitional using ISIN provision 7 CODE Number Number Number Number of voting % of voting rights of of of rights Shares Voting shares Rights Direct Direct Indirect Direct Indirect Ordinary 780,842 780,842 780,842 0.59% shares GB0003104196 B: Financial InstrumentsResulting situation after the triggering transaction Type of Expiration Exercise/ Number of voting % of voting financial date Conversion rights that may rights instrument Period/ Date be acquired if the instrument is exercised/ converted NIL Total (A+B)Number of voting rights % of voting rights 780,842 0.59%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

FMR CorpFMRCO10. Name of the Proxy holder:FMR Corp

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

As discussed with the FSA, prior to the implementation of the EU Transparency Directive, we aggregated the interests in shares of FMR Corp (FMR) and Fidelity International Limited (FIL). According to the new DTR rules we are now reporting the indirect holdings of FMR and FIL separately. A separate notification is being submitted for FIL Corp. Please note these holdings are correct as of close of business 16 March 2007.

14. Contact name:

Christopher Pearce or James Malthouse 01932 865065

Proteome Sciences PLCThilo Hoffmann 020 7426 9000Teather & Greenwood Limited15. Contact telephone number:

PROTEOME SCIENCES PLC
Date   Source Headline
1st Jun 20267:00 amRNSDirectorate Changes
14th May 202612:55 pmRNSResult of AGM
14th May 202612:00 pmRNSAnnual General Meeting Statement
15th Apr 20267:00 amRNSFinal results for the year ended 31 December 2025
4th Feb 202611:08 amRNSHolding(s) in Company
3rd Feb 202612:43 pmRNSHolding(s) in Company
28th Jan 20263:31 pmRNSResult of Oversubscribed Retail Offer
26th Jan 20267:05 amRNSRetail Offer to raise up to £60,000
26th Jan 20267:00 amRNS£840,000 Fundraise and Retail Offer
6th Jan 20267:00 amRNSTwo Further Substantial Contracts for PRM
8th Dec 20257:00 amRNSSubstantial contract for Proteome Sciences
25th Nov 20257:00 amRNSAppointment of Nominated Adviser and Broker
25th Sep 20257:00 amRNSInterim Results
16th May 20251:17 pmRNSResult of AGM
16th May 202512:00 pmRNSAGM Statement
10th Apr 20257:00 amRNSFinal Results
4th Apr 20251:00 pmRNSNotice of Results and Investor Presentation
21st Feb 20257:00 amRNSContract Win
23rd Dec 20247:08 amRNSLoan Facility, Trading Update & Directorate Change
13th Sep 20247:00 amRNSInterim Results and Directorate Change
16th May 20241:10 pmRNSResult of AGM
16th May 20247:00 amRNSAGM Statement
26th Apr 20247:00 amRNSContract Win
10th Apr 20247:00 amRNSFinal Results
2nd Jan 20247:00 amRNSCompletion of new facility in San Diego
30th Nov 20237:00 amRNSTrading Update
2nd Oct 20237:00 amRNSLaunch of Single Cell Proteomics Services
30th Aug 20232:14 pmRNSInvestor Presentation
25th Aug 20237:00 amRNSInterim Results
1st Jun 20239:43 amRNSRepayment of Loan
17th May 20231:05 pmRNSResult of AGM
17th May 20237:00 amRNSAGM Statement
12th May 20237:00 amRNSExpansion into the US
14th Apr 202310:45 amRNSDirector/PDMR Shareholding
6th Apr 202311:34 amRNSDirector/PDMR Shareholding
6th Apr 202310:30 amRNSInvestor Presentation
4th Apr 20237:00 amRNSFinal Results
29th Mar 20237:00 amRNSNotice of Results
6th Mar 20234:35 pmRNSPrice Monitoring Extension
20th Feb 20237:00 amRNSTrading Update
5th Jan 20237:00 amRNSMilestone Payment for TMT®/TMTpro™ Sales
1st Dec 20224:38 pmRNSGrant of Options and PDMR/director shareholdings
12th Oct 20227:00 amRNSGrant of Options and PDMR/director shareholdings
4th Oct 20227:00 amRNSChange of Auditor
20th Sep 20224:40 pmRNSSecond Price Monitoring Extn
20th Sep 20224:35 pmRNSPrice Monitoring Extension
18th Aug 20227:00 amRNSAppointment of Chief Financial Officer
11th Aug 20227:00 amRNSInvestor Presentation
4th Aug 20227:00 amRNSInterim Results
3rd Aug 20227:00 amRNSMilestone towards Single Cell Proteomics services

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.